Entrada Therapeutics

(NASDAQ) TRDA

Current Price$6.84

Market Cap$265.53M

Since IPO (2021)-71%

5 YearN/A

1 Year-21%

1 Month-52%

Entrada Therapeutics Financials at a Glance

Market Cap

$265.53M

Revenue (TTM)

$5.74M

Net Income (TTM)

$166.12M

EPS (TTM)

$-4.00

P/E Ratio

-1.71

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.84

Volume

46,232

Open

$6.56

Price

$6.84

Volume

46,232

Open

$6.56

Previous Close

$6.84

Daily Range

$6.02 - $6.86

52-Week Range

$4.93 - $16.45

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$6.84

Volume

46,232

Open

$6.56

Previous Close

$6.84

Daily Range

$6.02 - $6.86

52-Week Range

$4.93 - $16.45

TRDA News

Entrada (TRDA) Q2 Revenue Drops 98%

Motley Fool Markets TeamAug 6, 2025

TRDA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Entrada Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

152

CEO

Dipal Doshi, MBA

Website

www.entradatx.com

Headquarters

Boston, MA 02210, US

TRDA Financials

Key Financial Metrics (TTM)

Gross Margin

-6%

Operating Margin

-31%

Net Income Margin

-29%

Return on Equity

-48%

Return on Capital

-56%

Return on Assets

-50%

Earnings Yield

-58.48%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$265.53M

Shares Outstanding

38.82M

Volume

46.23K

Avg. Volume

287.88K

Financials (TTM)

Gross Profit

$21.32M

Operating Income

$156.00M

EBITDA

$142.40M

Operating Cash Flow

$128.51M

Capital Expenditure

$1.04M

Free Cash Flow

$129.55M

Cash & ST Invst.

$295.70M

Total Debt

$50.93M

Entrada Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$875.00K

-95.7%

Gross Profit

$70.00K

-99.7%

Gross Margin

8.00%

N/A

Market Cap

$265.53M

N/A

Market Cap/Employee

$1.45M

N/A

Employees

183

N/A

Net Income

$39.72M

-128.9%

EBITDA

$42.30M

-103.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$205.11M

-37.0%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$45.47M

-9.9%

Short Term Debt

$4.28M

-34.2%

Return on Assets

-49.51%

N/A

Return on Invested Capital

-56.40%

N/A

Free Cash Flow

$41.74M

-5.3%

Operating Cash Flow

$41.70M

-8.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ARCTArcturus Therapeutics Holdings Inc.

ARCTArcturus Therapeutics Holdings Inc.$9.22+3.60%

ACHVAchieve Life Sciences, Inc.

ACHVAchieve Life Sciences, Inc.$5.21+8.77%

SGMTSagimet Biosciences Inc.

SGMTSagimet Biosciences Inc.$7.71+0.92%

VYGRVoyager Therapeutics, Inc.

VYGRVoyager Therapeutics, Inc.$4.05+2.27%

IMRXImmuneering Corporation

IMRXImmuneering Corporation$5.22+0.00%

HUMAHumacyte, Inc.

HUMAHumacyte, Inc.$1.06-1.85%

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$6.28-1.72%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

RXTRackspace Technology

RXTRackspace Technology$5.49+0.56%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.62+0.08%

IRENIren

IRENIren$61.20+0.08%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.28+0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.57-0.07%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.35+0.01%

BBBlackBerry

BBBlackBerry$6.37+0.04%

Questions About TRDA

What is the current price of Entrada Therapeutics?

Entrada Therapeutics is trading at $6.84 per share.

What is the 52-week range for Entrada Therapeutics?

Over the past 52 weeks, Entrada Therapeutics has traded between $4.93 and $16.45.

How much debt does Entrada Therapeutics have?

As of the most recent reporting period, Entrada Therapeutics reported total debt of $49.75M.

How much cash does Entrada Therapeutics have on hand?

Entrada Therapeutics reported $76.44M in cash and cash equivalents in its most recent financial results.

What is Entrada Therapeutics’s dividend yield?

Entrada Therapeutics does not currently have a dividend yield.

Entrada Therapeutics

Entrada Therapeutics Financials at a Glance

TRDA News

Entrada (TRDA) Q2 Revenue Drops 98%

TRDA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Entrada Therapeutics

TRDA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Entrada Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TRDA

What is the current price of Entrada Therapeutics?

What is the 52-week range for Entrada Therapeutics?

How much debt does Entrada Therapeutics have?

How much cash does Entrada Therapeutics have on hand?

What is Entrada Therapeutics’s dividend yield?

Premium Investing Services